| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/14/2002 | WO2002020480A1 Substituted fused pyrroleimines and pyrazoleimines |
| 03/14/2002 | WO2002020479A1 Substituted oxindole derivatives as tyrosine kinase inhibitors |
| 03/14/2002 | WO2002020478A1 N-benzylindole-3-acetic acid derivatives for use in the treatment of drug resistan cancer |
| 03/14/2002 | WO2002020475A2 Inhibitors of serine protease activity of matriptase or mtsp1 |
| 03/14/2002 | WO2002020474A2 Resorcinol derivatives |
| 03/14/2002 | WO2002020466A1 Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents |
| 03/14/2002 | WO2002020464A2 Benzene tricarboxylic acid amides as insulin receptor activators |
| 03/14/2002 | WO2002020457A1 Dihydroxy open-acid salt of simvastatin |
| 03/14/2002 | WO2002020091A2 Antithrombotic compositions |
| 03/14/2002 | WO2002020090A2 Pharmaceutical compositions |
| 03/14/2002 | WO2002020058A1 Preparations for oral administration |
| 03/14/2002 | WO2002020057A2 Flavoring systems for pharmaceutical compositions and methods of making such compositions |
| 03/14/2002 | WO2002020032A1 Stat3 agonists and antagonists and therapeutic uses thereof |
| 03/14/2002 | WO2002020026A2 Treatment of drug resistant organisms with nitric oxide |
| 03/14/2002 | WO2002020024A1 Purine ribosides as antiarrhythmics |
| 03/14/2002 | WO2002020023A1 Methods and compositions for potentiating cancer chemotherapeutic agents |
| 03/14/2002 | WO2002020022A1 Method of treating neurologic disorders |
| 03/14/2002 | WO2002020021A1 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications |
| 03/14/2002 | WO2002020020A1 Exemestane as chemopreventing agent |
| 03/14/2002 | WO2002020019A1 New use of quetiapine |
| 03/14/2002 | WO2002020018A1 Tablets containing epinastine manufactured by direct compression |
| 03/14/2002 | WO2002020017A2 Use of ectoin or ectoin derivatives for stabilizing p53 |
| 03/14/2002 | WO2002020016A1 AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA α7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY |
| 03/14/2002 | WO2002020015A1 Inhibitors of prenyl-protein transferase |
| 03/14/2002 | WO2002020014A1 Incompetitive inhibitors of helicase primase |
| 03/14/2002 | WO2002020013A2 A method for treating allergies using substituted pyrazoles |
| 03/14/2002 | WO2002020012A2 Method for treating allergies using substituted pyrazoles |
| 03/14/2002 | WO2002020011A2 A method for treating allergies using substituted pyrazoles |
| 03/14/2002 | WO2002020008A1 Inhibitors of nadh:ubiquinone oxidoreductase |
| 03/14/2002 | WO2002020007A1 Cathartic composition |
| 03/14/2002 | WO2002020006A1 Antiviral compounds and method of treating viral infections |
| 03/14/2002 | WO2002020004A1 Methods for inhibiting inflammatory disease |
| 03/14/2002 | WO2002020003A2 Use of carp inhibitors for the treatment of heart diseases |
| 03/14/2002 | WO2002020002A2 A method for treating allergies |
| 03/14/2002 | WO2002020001A2 Two-component anti-emetic composition comprising dexamethasone and metoclopramide |
| 03/14/2002 | WO2002020000A2 Combined estrogen blockade of the breast with exemestane and raloxifene |
| 03/14/2002 | WO2002019999A2 Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant |
| 03/14/2002 | WO2002019998A2 A method of treating weight gain associated with atypical antipsychotic use |
| 03/14/2002 | WO2002019997A1 Pde iii inhibitors for treating sexual dysfunction |
| 03/14/2002 | WO2002019996A2 Prevention of acute sinusitis and sinus attack |
| 03/14/2002 | WO2002019995A2 Pharmaceutical combination containing salmeterol and fluticasone |
| 03/14/2002 | WO2002019994A2 The treatment of inflammatory disorders |
| 03/14/2002 | WO2002019993A1 Granular preparations for oral administration |
| 03/14/2002 | WO2002019990A1 Modified release formulation |
| 03/14/2002 | WO2002019985A2 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure |
| 03/14/2002 | WO2002019982A2 Cosmetic composition and method for reducing or preventing wrinkling |
| 03/14/2002 | WO2002019981A2 Cosmetic and pharmaceutical composition comprising chelating/sequestering agents and their cosmetic and dermatological use |
| 03/14/2002 | WO2002019980A1 Composition of vitamin c and/or vitamin a |
| 03/14/2002 | WO2002019978A2 Use of ectoine or ectoine derivatives for oral care |
| 03/14/2002 | WO2002019975A1 Hair growth stimulants |
| 03/14/2002 | WO2002019972A2 Stabilized ascorbic acid solutions |
| 03/14/2002 | WO2002019969A2 (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents |
| 03/14/2002 | WO2002019967A2 Substituted hydrazine derivatives |
| 03/14/2002 | WO2002019966A2 Cardiac arrhythmia treatment methods |
| 03/14/2002 | WO2002019965A2 Heat shock response and virus replication |
| 03/14/2002 | WO2002019964A2 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions |
| 03/14/2002 | WO2002019962A2 Therapeutic and cosmetic uses of heparanases |
| 03/14/2002 | WO2002019961A2 Pharmaceutical compositions for headache, migraine, nausea and emesis |
| 03/14/2002 | WO2002019894A2 Methods for analyzing and using data from hypertensive patients |
| 03/14/2002 | WO2002004405A3 13-substituted methacycline compounds |
| 03/14/2002 | WO2001093890A3 Botulinum toxin implant |
| 03/14/2002 | WO2001093827A3 Neurotoxin implant |
| 03/14/2002 | WO2001090189A3 G-protein coupled receptor org3. |
| 03/14/2002 | WO2001085981A3 Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis |
| 03/14/2002 | WO2001082909A3 2-acyl indol derivatives and their use as anti-tumour agents |
| 03/14/2002 | WO2001079502A3 Vectors for gene therapy |
| 03/14/2002 | WO2001078696A3 Formulations for use in inhaler devices |
| 03/14/2002 | WO2001078695A3 Pharmaceutical formulations for dry powder inhalers |
| 03/14/2002 | WO2001078694A3 Formulations for use in inhaler devices |
| 03/14/2002 | WO2001076644A3 Lipid-based systems for targeting diagnostic agents |
| 03/14/2002 | WO2001076555A3 Lipid-based drug delivery systems for topical application |
| 03/14/2002 | WO2001074790A3 Novel compounds for enhancing chemotherapy |
| 03/14/2002 | WO2001072290A3 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 03/14/2002 | WO2001070757A3 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 03/14/2002 | WO2001070734A3 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 03/14/2002 | WO2001070692A3 Heterocyclic acylsulfimides, a method for their production, agents containing the same and their use as pesticides |
| 03/14/2002 | WO2001070673A3 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
| 03/14/2002 | WO2001070668B1 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 03/14/2002 | WO2001068612A3 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof |
| 03/14/2002 | WO2001066553A3 Novel aryl fructose-1,6-bisphosphatase inhibitors |
| 03/14/2002 | WO2001066543A3 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| 03/14/2002 | WO2001066119A3 Pharmaceutical compositions including alginates |
| 03/14/2002 | WO2001066093A3 Sustained release ranolazine formulations |
| 03/14/2002 | WO2001066081A3 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 03/14/2002 | WO2001064668A3 1,3-dihydro-2h-indol-2-one, and their use as v1b or both v1b and v1a arginine-vasopressin ligand receptors |
| 03/14/2002 | WO2001062737A3 Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| 03/14/2002 | WO2001060781A3 Diphenyl compounds, formulations and uses thereof |
| 03/14/2002 | WO2001059129A3 Mammalian secreted group iii phospholipase a2 |
| 03/14/2002 | WO2001059126A3 Gene cluster encoding a nystatin polyketide synthase and its manipulation and utility |
| 03/14/2002 | WO2001058921A9 Methods and compositions for generating angiostatin |
| 03/14/2002 | WO2001058918A3 Oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments |
| 03/14/2002 | WO2001058852A3 (r)-2-aryl-propionamides, useful in the inhibition of il-8-induced chemiotaxis of neutrophils |
| 03/14/2002 | WO2001055134A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 03/14/2002 | WO2001055130A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 03/14/2002 | WO2001054707A3 Modification of surface proteins by aminopeptidase inhibitors |
| 03/14/2002 | WO2001054659A3 Slimming cosmetic composition comprising a plant extract containing a plant natriuretic peptide (pnp) |
| 03/14/2002 | WO2001052897A3 Therapeutic anti-inflammatory and analgesic composition containing selective cox-2 inhibitors |
| 03/14/2002 | WO2001052826A3 Novel podophyllotoxin compositions |
| 03/14/2002 | WO2001049264A3 Pharmaceutical compositions for oral administration |
| 03/14/2002 | WO2001048162A3 Method for the production of vitamin a |